The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer
Abstract
Pancreatic cancer remains one of the most highly lethal diseases with very poor prognosis. Gemcitabine (GEM) is the first-line chemotherapeutic drug for pancreatic cancer treatment but is associated with significant side effects when administered systemically. Exosomes have emerged as attractive candidates for drug delivery for their high delivery efficiency and biocompatibility. Here, GEM was loaded into autologous exosomes to formulate ExoGEM for targeted chemotherapy of pancreatic cancer. Autologous exosomes facilitate cellular uptake of GEM and contributed to significantly increased cytotoxic effect of GEM, while heterologous cellular uptake showed less efficiency. Autologous exosomes showed targeting ability to pancreatic cancer in biodistribution study, and GEM concentration in tumor site was increased via ExoGEM delivery. ExoGEM treatment, in tumor-bearing mice, significantly suppressed tumor growth, with prolonged survival in a dose-response manner, but caused minimal damage to normal tissues. More importantly, tumors in several mice treated with ExoGEM were disappeared without recurrence. Autologous exosomes are safe and effective vehicles for targeted delivery of GEM against pancreatic cancer. This delivery strategy may have implications for personalized chemotherapy of pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Shedding light on the cell biology of extracellular vesicles
van Niel, G., D'Angelo, G., & Raposo, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.125 · Cited by 8,369
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Biological properties of extracellular vesicles and their physiological functions
Yáñez‐Mó, M., Siljander, P. R. ‐., Andreu, Z., Bedina Zavec, A., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27066 · Cited by 5,926
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Communication by Extracellular Vesicles: Where We Are and Where We Need to Go
Tkach, M., & Théry, C. (2016) · Cell · doi:10.1016/j.cell.2016.01.043 · Cited by 3,444
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
Kamisawa, T., Wood, L. D., Itoi, T., & Takaori, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00141-0 · Cited by 2,212
Exosomes as drug delivery vehicles for Parkinson’s disease therapy
Haney, M. J., Klyachko, N. L., Zhao, Y., Gupta, R., Plotnikova, E. G., He, Z., Patel, T., Piroyan, A., Sokolsky, M., Kabanov, A. V., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.033 · Cited by 2,009
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O'Reilly, D. A., Cunningham, D., Wadsley, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32409-6 · Cited by 1,926
New Technologies for Analysis of Extracellular Vesicles
Shao, H., Im, H., Castro, C. M., Breakefield, X., Weissleder, R., & Lee, H. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00534 · Cited by 1,675
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
Extracellular Vesicles: Unique Intercellular Delivery Vehicles
Maas, S. L. N., Breakefield, X. O., & Weaver, A. M. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.11.003 · Cited by 1,429
Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells
Kim, M. S., Haney, M. J., Zhao, Y., Mahajan, V., Deygen, I., Klyachko, N. L., Inskoe, E., Piroyan, A., Sokolsky, M., Okolie, O., et al. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.10.012 · Cited by 1,410
Exosome-Mediated Metastasis: Communication from a Distance
Wortzel, I., Dror, S., Kenific, C. M., & Lyden, D. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.011 · Cited by 1,285
Exosomes: Therapy delivery tools and biomarkers of diseases
Barile, L., & Vassalli, G. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.020 · Cited by 1,038
Sokolova, V., Ludwig, A.-K., Hornung, S., Rotan, O., Horn, P. A., Epple, M., & Giebel, B. (2011) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2011.05.013 · Cited by 851
Cellular pharmacology of gemcitabine
Mini, E., Nobili, S., Caciagli, B., Landini, I., & Mazzei, T. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj941 · Cited by 842
Biocompatibility of engineered nanoparticles for drug delivery
Naahidi, S., Jafari, M., Edalat, F., Raymond, K., Khademhosseini, A., & Chen, P. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.12.013 · Cited by 809
Biodistribution and delivery efficiency of unmodified tumor-derived exosomes
Smyth, T., Kullberg, M., Malik, N., Smith-Jones, P., Graner, M. W., & Anchordoquy, T. J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.013 · Cited by 722
Kim, M. S., Haney, M. J., Zhao, Y., Yuan, D., Deygen, I., Klyachko, N. L., Kabanov, A. V., & Batrakova, E. V. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.09.011 · Cited by 663
The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications
Chao, M. P., Weissman, I. L., & Majeti, R. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.01.010 · Cited by 649
Saari, H., Lázaro-Ibáñez, E., Viitala, T., Vuorimaa-Laukkanen, E., Siljander, P., & Yliperttula, M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.031 · Cited by 613
Kim, S. M., Yang, Y., Oh, S. J., Hong, Y., Seo, M., & Jang, M. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.013 · Cited by 481
Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine
Fais, S., O’Driscoll, L., Borras, F. E., Buzas, E., Camussi, G., Cappello, F., Carvalho, J., Cordeiro da Silva, A., Del Portillo, H., El Andaloussi, S., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b08015 · Cited by 481
Yan, W., Wu, X., Zhou, W., Fong, M. Y., Cao, M., Liu, J., Liu, X., Chen, C.-H., Fadare, O., Pizzo, D. P., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0083-6 · Cited by 469
Self-citationThe role of exosomes in cancer metastasis
Steinbichler, T. B., Dudás, J., Riechelmann, H., & Skvortsova, I.-I. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.02.006 · Cited by 389
Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment
Chen, B., Dai, W., He, B., Zhang, H., Wang, X., Wang, Y., & Zhang, Q. (2017) · Theranostics · doi:10.7150/thno.16684 · Cited by 342
Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics
Lorenzer, C., Dirin, M., Winkler, A.-M., Baumann, V., & Winkler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.003 · Cited by 284
Strategic design of extracellular vesicle drug delivery systems
Armstrong, J. P. K., & Stevens, M. M. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.017 · Cited by 257
A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer
Li, Y., Gao, Y., Gong, C., Wang, Z., Xia, Q., Gu, F., Hu, C., Zhang, L., Guo, H., & Gao, S. (2018) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2018.05.020 · Cited by 222
Self-citationLipid nanoparticles for targeted siRNA delivery - going from bench to bedside
Zatsepin (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s106625 · Cited by 162
Effects of systemic chemotherapy on the liver
Ramadori, G., & Cameron, S. (2010) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31651-5 · Cited by 132
Anticancer Drug-Induced Acute Kidney Injury
Izzedine, H., & Perazella, M. A. (2017) · Kidney International Reports · doi:10.1016/j.ekir.2017.02.008 · Cited by 118
A novel platform for cancer therapy using extracellular vesicles
Tominaga, N., Yoshioka, Y., & Ochiya, T. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.002 · Cited by 112
Ingato, D., Edson, J. A., Zakharian, M., & Kwon, Y. J. (2018) · ACS Nano · doi:10.1021/acsnano.8b05377 · Cited by 108
Exploitation of Exosomes as Nanocarriers for Gene-, Chemo-, and Immune-Therapy of Cancer
Srivastava, A., Babu, A., Filant, J., Moxley, K., Ruskin, R., Dhanasekaran, D. N., Sood, A., McMeekin, S., & Ramesh, R. (2016) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2016.2205 · Cited by 96
Middleton, G., Palmer, D. H., Greenhalf, W., Ghaneh, P., Jackson, R., Cox, T. F., Evans, A. G., Shaw, V. E., Wadsley, J., Valle, J. W., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30084-0 · Cited by 77
Nanotechnology for delivery of gemcitabine to treat pancreatic cancer
Birhanu, G., Javar, H. A., Seyedjafari, E., & Zandi‐Karimi, A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.071 · Cited by 76
Enhanced Tumor Delivery of Gemcitabine via PEG-DSPE/TPGS Mixed Micelles
Wang, Y., Fan, W. Q., Dai, X., Katragadda, U., Mckinley, D., Teng, Q., & Tan, C. (2014) · Molecular Pharmaceutics · doi:10.1021/mp4005904 · Cited by 75
Ruiss, R., Jochum, S., Mocikat, R., Hammerschmidt, W., & Zeidler, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025294 · Cited by 73
Wan, X., Zhang, J., Yu, W., Shen, L., Ji, S., & Hu, T. (2016) · Process Biochemistry · doi:10.1016/j.procbio.2016.09.029 · Cited by 57
Synthetic SiRNA Delivery: Progress and Prospects
Roberts, T. C., Ezzat, K., Andaloussi, S. E., & Weinberg, M. S. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3112-5_23 · Cited by 56
Jain, S., Jain, R., Das, M., Agrawal, A. K., Thanki, K., & Kushwah, V. (2014) · RSC Advances · doi:10.1039/c4ra04237a · Cited by 45
Kaiser, J. (2016) · Science · doi:10.1126/science.352.6282.164 · Cited by 39
Li, Y., Wu, J., Hu, X.-B., Wang, J., & Xiang, D. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0286 · Cited by 27
Self-citationHaney, M. J., Klyachko, N. L., Zhao, Y., Kabanov, A. V., & Batrakova, E. V. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.396 · Cited by 14
Cited by
The role of extracellular vesicles in cancer
Kalluri, R., & McAndrews, K. M. (2023) · Cell · doi:10.1016/j.cell.2023.03.010 · Cited by 664
Exosome engineering: Current progress in cargo loading and targeted delivery
Fu, S., Wang, Y., Xia, X., & Zheng, J. C. (2020) · NanoImpact · doi:10.1016/j.impact.2020.100261 · Cited by 444
Hybrid exosomes, exosome-like nanovesicles and engineered exosomes for therapeutic applications
Mondal, J., Pillarisetti, S., Junnuthula, V., Saha, M., Hwang, S. R., Park, I.-K., & Lee, Y.-K. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.027 · Cited by 416
Challenges in the development and establishment of exosome-based drug delivery systems
Wang, J., Chen, D., & Ho, E. A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.020 · Cited by 382
Self-citationGurunathan, S., Kang, M.-H., & Kim, J.-H. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s291956 · Cited by 379
Metadata
- Authors
- Li, Y.-J., Wu, J.-Y., Wang, J.-M., Hu, X.-B., Cai, J.-X., & Xiang, D.-X.
- Venue
- Acta Biomaterialia
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 101
- Pages
- 519-530
- ISSN
- 1742-7061 (ISSN-L)
- OpenAlex
- W2980637827
- Cited by
- 291
- References
- 52
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.